Progression-free survival, overall survival and quality of life: What is their medicoeconomic importance in oncology? - 09/11/16
the participants of Round Table no 3 of Giens XXXI
Pascal Bilbault e, Anne-Françoise Gaudin f, Claire Le Jeunne g, Olivier Lalaude h, Stéphane Roze i, Rima de Sahb j, Claudine Sapède kpages | 8 |
Iconographies | 2 |
Vidéos | 0 |
Autres | 0 |
Summary |
Medico-economic evaluations estimate, for a given health technology, the added cost and the clinical benefit compared to a reference strategy. The objective here is to analyze the criteria used to measure clinical benefit as the basis for market access and reimbursement decisions for drugs in oncology both in France and in Europe. Prolonged overall survival is the criterion of choice to demonstrate the benefit of an anticancer drug; a survival gain of 2 to 3 months or more would be considered as relevant for a new product versus the comparator. In the absence of survival benefit or mature data on survival, progression-free survival or symptom-free survival and the availability of alternative curative treatments, decrease in drug toxicity and quality of life improvement may be considered. Differences in clinical benefit assessment between regulatory agencies and payers are not specific to France. Case studies show that it is difficult to find a consistency in reimbursement and pricing decisions and to identify factors that may fully explain reimbursement decisions when survival benefit is not demonstrated.
Le texte complet de cet article est disponible en PDF.Keywords : Medico-economic evaluation, Oncology, Survival, Progression-free survival, Incremental cost-effectiveness ratio, French Drug Authority (Haute Autorité de santé [HAS]), NICE, IQWIG
Plan
☆ | Articles, analyses and proposals from the Giens Workshops are those of the authors and do not prejudice the proposition of their parent organization. |
Vol 71 - N° 6
P. 625-632 - décembre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?